The Cooper Companies, Inc. (NASDAQ:COO) Shares Sold by Corient Private Wealth LLC

Corient Private Wealth LLC trimmed its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 19.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 97,605 shares of the medical device company's stock after selling 23,538 shares during the quarter. Corient Private Wealth LLC's holdings in Cooper Companies were worth $8,973,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Byrne Asset Management LLC acquired a new stake in shares of Cooper Companies in the fourth quarter valued at $33,000. OFI Invest Asset Management purchased a new position in Cooper Companies during the 4th quarter valued at about $34,000. Brown Brothers Harriman & Co. grew its position in Cooper Companies by 191.0% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company's stock valued at $46,000 after acquiring an additional 275 shares in the last quarter. West Financial Advisors LLC purchased a new stake in Cooper Companies during the fourth quarter worth about $49,000. Finally, Atala Financial Inc acquired a new stake in shares of Cooper Companies during the fourth quarter worth about $51,000. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

COO has been the topic of several recent research reports. Piper Sandler reaffirmed an "overweight" rating and set a $115.00 target price (down from $120.00) on shares of Cooper Companies in a research note on Friday, March 7th. StockNews.com cut Cooper Companies from a "buy" rating to a "hold" rating in a research note on Wednesday, December 11th. BNP Paribas raised Cooper Companies to a "hold" rating in a research note on Thursday, March 13th. Needham & Company LLC reissued a "hold" rating on shares of Cooper Companies in a research report on Friday, March 7th. Finally, JPMorgan Chase & Co. decreased their price target on Cooper Companies from $120.00 to $110.00 and set an "overweight" rating for the company in a report on Friday, March 7th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $110.25.

Remove Ads

Cooper Companies Stock Performance

COO traded down $0.37 during trading on Tuesday, hitting $83.70. 1,669,122 shares of the stock were exchanged, compared to its average volume of 1,287,437. The firm has a market capitalization of $16.74 billion, a P/E ratio of 42.92, a PEG ratio of 2.25 and a beta of 1.02. The Cooper Companies, Inc. has a 1-year low of $77.05 and a 1-year high of $112.38. The stock has a fifty day moving average price of $89.90 and a two-hundred day moving average price of $97.88. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, hitting analysts' consensus estimates of $0.92. The firm had revenue of $964.70 million during the quarter, compared to analysts' expectations of $981.25 million. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. As a group, sell-side analysts predict that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.